ERBB2 and invasive breast carcinoma: Of the 3853 female patients newly diagnosed with stage II or III HER2-negative primary invasive breast cancer for whom ER and PR continuous expression data were available, 3055 patients met the study criteria included in the analysis (Supplementary Fig. S1).